The firm's first candidate, AP003, will focus on rare genetic liver diseases caused by nonsense mutations that prematurely halt protein production.
Results that may be inaccessible to you are currently showing.
Hide inaccessible resultsResults that may be inaccessible to you are currently showing.
Hide inaccessible results